Monday, November 11, 2024 11:04:43 PM
"Successfully negotiating with companies from the top 10 pharma giants:"
https://www.pharmaceutical-technology.com/features/top-ten-pharma-companies-in-2023/
1. Johnson & Johnson- $85.2bn
2. F. Hoffmann-La Roche Ltd- $66.4bn
3. Merck & Co – $60.1bn
4. Pfizer – $58.5bn
5. AbbVie – $54.3bn
6. Bayer – $51.9bn
7. Sanofi– $46.9bn
8. AstraZeneca – $45.8bn
9. Novartis– $45.4bn
10. Bristol Myers Squibb- $45.0bn
"The interest and attention our breakthrough gene editing technology has garnered, particularly in its application for drug development, is truly gratifying."
___
Shmn baby pharma/biotech at .0011 ?
https://www.pharmaceutical-technology.com/features/top-ten-pharma-companies-in-2023/
1. Johnson & Johnson- $85.2bn
2. F. Hoffmann-La Roche Ltd- $66.4bn
3. Merck & Co – $60.1bn
4. Pfizer – $58.5bn
5. AbbVie – $54.3bn
6. Bayer – $51.9bn
7. Sanofi– $46.9bn
8. AstraZeneca – $45.8bn
9. Novartis– $45.4bn
10. Bristol Myers Squibb- $45.0bn
"The interest and attention our breakthrough gene editing technology has garnered, particularly in its application for drug development, is truly gratifying."
We are pleased to share that the company is successfully negotiating with a diverse range of companies, from the top 10 pharmaceutical giants to small private firms, regarding the ABBIE kits. Detailed information will be provided once we finalize the contracts, sales, delivery…
— SOHM, Inc. (@sohminc) November 11, 2024
___
Shmn baby pharma/biotech at .0011 ?
Recent SHMN News
- SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery • ACCESS Newswire • 11/06/2025 02:30:00 PM
- SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development • ACCESS Newswire • 11/04/2025 02:30:00 PM
